We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.31%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$118M
AUM Growth
+$4.41M
Cap. Flow
-$8.19M
Cap. Flow %
-6.92%
Top 10 Hldgs %
44.84%
Holding
84
New
17
Increased
12
Reduced
22
Closed
11

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$6.63M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.31M
3
CLLS
Cellectis
CLLS
+$1.61M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$1.21M
5
BLRX
BioLineRX
BLRX
+$1.07M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$2.56M
2
AERI
Aerie Pharmaceuticals
AERI
+$2.3M
3
DERM
Dermira, Inc.
DERM
+$2.28M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.21M
5
TSRO
TESARO, Inc.
TSRO
+$2.08M

Sector Composition

Rank Sector Weight
1 Healthcare 85.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
51
Ascendis Pharma A/S
ASND
$16.5B
$510K 0.43%
18,214
-34,786
-66% -$879K
RCKT icon
52
Rocket Pharmaceuticals
RCKT
$343M
$474K 0.4%
59,284
– –
EIGR
53
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$412K 0.35%
1,199
-141
-11% -$48.6K
SRRA
54
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$405K 0.34%
+6,625
New +$385K
CBAY
55
DELISTED
Cymabay Therapeutics
CBAY
$379K 0.32%
+88,067
New +$253K
ABEO icon
56
Abeona Therapeutics
ABEO
$355M
$338K 0.29%
2,701
-371
-12% -$47.8K
CYAD
57
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$328K 0.28%
12,528
– –
MASI
58
DELISTED
Masimo
MASI
$326K 0.28%
3,500
-6,500
-65% -$535K
OBSV
59
DELISTED
ObsEva SA Ordinary Shares
OBSV
$260K 0.22%
+25,000
New +$307K
BLCM
60
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$247K 0.21%
+2,000
New +$262K
AXSM icon
61
Axsome Therapeutics
AXSM
$11.7B
$217K 0.18%
+55,700
New +$266K
AFMD
62
DELISTED
Affimed
AFMD
$213K 0.18%
+9,250
New +$203K
PVLA
63
Palvella Therapeutics
PVLA
$2.05B
$139K 0.12%
669
-2,123
-76% -$376K
DMK
64
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$128K 0.11%
+429
New +$108K
ANAB icon
65
AnaptysBio
ANAB
$1.54B
$125K 0.11%
+4,500
New +$105K
TNXP icon
66
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
TMBR
67
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$58K 0.05%
8
+3
+60% +$20.8K
SLS icon
68
SELLAS Life Sciences
SLS
$1.99B
$28K 0.02%
+31
New +$51.3K
ABUS icon
69
Arbutus Biopharma
ABUS
$847M
– –
-234,000
Closed -$573K
CYTK icon
70
Cytokinetics
CYTK
$10.6B
– –
-210,306
Closed -$2.56M
EPIX
71
DELISTED
ESSA Pharma
EPIX
– –
-4,902
Closed -$289K
PTGX icon
72
Protagonist Therapeutics
PTGX
$8.55B
– –
-45,586
Closed -$1M
AVGR
73
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
0
– -$93K
FSTX
74
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-6,853
Closed -$219K
CNCE
75
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-66,968
Closed -$689K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, DAFNA Capital Management held 84 positions worth $118M, up 3.9% from $114M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $8.19M in Q1 2017, closing 11 positions and reducing 22 holdings. Its most notable exit was Cytokinetics, an estimated $2.56M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Cellectis worth $1.83M.

  • DAFNA Capital Management's largest Q1 2017 buy was Cellectis: 76,404 shares worth $1.83M.
  • DAFNA Capital Management added most to Loxo Oncology, Inc in Q1 2017, an estimated $6.63M increase.
  • DAFNA Capital Management's biggest Q1 2017 reduction was Aerie Pharmaceuticals, cutting an estimated $2.3M.
  • DAFNA Capital Management fully exited Cytokinetics in Q1 2017, selling an estimated $2.56M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $118M portfolio in Q1 2017.
  • DAFNA Capital Management opened 17 new positions and closed 11 in Q1 2017.
  • DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $118M.

Based on DAFNA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.